GREY:IMVIF - Post by User
Comment by
Biotech010on Mar 05, 2021 2:22pm
257 Views
Post# 32730014
RE:RE:Q1 updates IMV
RE:RE:Q1 updates IMV In my recent discussion with the company we talked about the data and visibility among investors.
- For DLBCL we agree with you that the data with the biomarker is great but the comments that we get is that it is on a small number of patients but on the good side we plan to have data on much more patients in the last part of 2021 as we are heading full speed to the next clinical trial in DLBCL;
- I would also say that the fact that the investors cannot put us in a ‘bucket’ as a CAR-T company or an ADC company is making it more difficult. We need to demonstrate more to get the same recognition so it comes back to the number of patients.
That's why the next trial is so important, to get more patients so there can be noubt about DPX. The company is attending a conference next, I sure hope they will issue a press release on monday to get extra attention during the conference. It seems logic to me announce the results of the FDA meeting that took place last month so the analysts and investors know the path forward. And that's crucial for the stock price to rise :)